Teclistamab
- Generic Name
- Teclistamab
- Brand Names
- Tecvayli
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2119595-80-9
- Unique Ingredient Identifier
- 54534MX6Z9
- Background
Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds, allowing the drug to recruit CD3-expressing T cells to B...
- Indication
Teclistamab is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
- Conditions
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Multiple Myeloma Research Consortium
- Target Recruit Count
- 300
- Registration Number
- NCT06171685
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Carl Ola Landgren, MD, PhD
- Target Recruit Count
- 50
- Registration Number
- NCT06100237
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT05972135
- Locations
- 🇺🇸
Texas Oncology, Austin, Texas, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT05849610
- Locations
- 🇪🇸
Hospital Doce de Octubre, Madrid, Spain
🇪🇸Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
🇪🇸Hospital Virgen de la Arrixaca, Murcia, Spain
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇺🇸
Michael E DeBakey VA Medical Center, Houston, Texas, United States
🇨🇦Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇵🇹Uls Gaia Espinho, Vila Nova de Gaia, Portugal
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 74
- Registration Number
- NCT05572229
- Locations
- 🇫🇷
Chu Amiens - Hopital Sud, Amiens, France
🇫🇷Chru Angers, Angers, France
🇫🇷Ch D'Avignon, Avignon, France
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1590
- Registration Number
- NCT05552222
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South Hospital, Changsha, China
🇨🇳The First Affliated Hospital Of Nanchang University, Nanchang, China
🇦🇹SCRI CCCIT gem GmbH, Salzburg, Austria
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Irene Ghobrial, MD
- Target Recruit Count
- 52
- Registration Number
- NCT05469893
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05463939
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 74
- Registration Number
- NCT05338775
- Locations
- 🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.